Published in Genetics and Environmental Law Weekly, November 24th, 2007
More than 75 percent of patients treated in the study achieved tumor reductions across all dose levels evaluated, including four with partial responses. Twelve additional patients had stable disease and seven had progressive disease. Of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.